StocksMedium•5 November 2026•
1 min read
Monte Rosa Therapeutics Reports Positive Heart Drug Data and $87.5M Novartis Milestone
Key Facts
1Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102 in treating atherosclerotic cardiovascular disease.
2Novartis initiated Phase 2 studies for MRT-6160, triggering $87.5 million in milestone payments to Monte Rosa.
3The company holds $582.6 million in cash and securities, expected to fund operations into 2029.
Monte Rosa Therapeutics announced positive Phase 1 results for its drug candidate MRT-8102, designed to treat atherosclerotic cardiovascular disease. According to a statement on GlobeNewswire, the company's partner Novartis has initiated Phase 2 studies for MRT-6160, triggering an $87.5 million milestone payment to Monte Rosa.
The company maintains a strong financial position with $582.6 million in cash and securities, which is expected to fund its operations into 2029. Shares of GLUE closed at $10.82 on November 4, 2026, while Novartis (NVS) closed at $164.98 on the same day.